The next session of #RheumJC will be Wednesday, December 14. We’ll be discussing four of your favorite abstracts from the 2016 ACR Annual Meeting based on your votes from our recent poll.
- First session: 5pm Eastern Time (find this in your time zone)
- Second second: 10pm Eastern Time (find this in your time zone)
The abstracts we’ll be discussing are:
Abstract 911 – Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (48%, 14 Votes)
Abstract 1955 – Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (41%, 12 Votes)
Abstract 3028 – A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (38%, 11 Votes)
Abstract 1725 – Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (34%, 10 Votes)
We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.
- Please remember to try to stay on topic whenever possible.
- Be polite and courteous.
- Do not violate HIPAA.